Advanced Research in New Drugs for Neurodegenerative Diseases
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 236
Special Issue Editor
Interests: functional neuroanatomy; neural mechanisms responsible for motivational behaviors including stress, drugs of abuse, learning and memory; development of new drugs for neurodegenerative disease like Parkinson's, Alzheimer's disease, Ischemia
Special Issue Information
Dear Colleagues,
Neurodegenerative diseases are characterized by the progressive loss of neurons which results in the decline of cognitive and motor functions. Even though recent research has made remarkable progress in understanding the etiology and causes of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, or Huntington’s disease, the detailed triggers and mechanisms of neurodegeneration remain unknown.
Recently, a number of possible mechanisms of neurodegeneration have been suggested thanks to new findings and technologies. Neurodegenerative diseases share a common pathological phenotype such as the accumulation of specific misfolded and aggregated proteins, mitochondrial dysfunction, oxidative stress, and neuro-inflammation in the brain. The key targets that are implicated in various neurological diseases have been identified and there are mechanistic links between these key targets and neurodegenerative diseases.
This Special Issue of Biomedicines aims to update our knowledge on the underlying pathogenic mechanisms and novel therapeutic interventions for neurodegenerative disorders, providing new insight for their valid and effective treatment strategies.
Prof. Dr. Insop Shim
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neurodegeneration
- cell death
- oxidative stress
- neuro-inflammation
- new drugs
- natural products
